Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2

Bioorg Med Chem. 2009 Jan 15;17(2):905-18. doi: 10.1016/j.bmc.2008.11.032. Epub 2008 Nov 19.

Abstract

The identification, synthesis and evaluation of a series of rhodanine and thiazolidin-2,4-dione derivatives as selective inhibitors of human arylamine N-acetyltransferase 1 and mouse arylamine N-acetyltransferase 2 is described. The most potent inhibitors identified have submicromolar activity and inhibit both the recombinant proteins and human NAT1 in ZR-75 cell lysates in a competitive manner. (1)H NMR studies on purified mouse Nat2 demonstrate that the inhibitors bind within the putative active site of the enzyme.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arylamine N-Acetyltransferase / antagonists & inhibitors*
  • Binding Sites
  • Biomarkers, Tumor / antagonists & inhibitors
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Enzyme Inhibitors
  • Female
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Mice
  • Rhodanine / chemical synthesis*
  • Rhodanine / pharmacology
  • Thiazolidinediones / chemical synthesis*
  • Thiazolidinediones / pharmacology

Substances

  • Biomarkers, Tumor
  • Enzyme Inhibitors
  • Isoenzymes
  • Thiazolidinediones
  • thiazolidine-2,4-dione
  • Rhodanine
  • Arylamine N-Acetyltransferase
  • N-acetyltransferase 1
  • Nat2 enzyme, mouse